Selection of patients eligible for implantable cardioverter defibrillator: beyond left ventricular ejection fraction.

The selection of patients eligible for implantable cardioverter defibrillator (ICD), in primary prevention, is a critical moment in the management of the patients with cardiomyopathies as it needs a right balance of the patients' arrhythmic risk and the risks related to the implantation, as well as the device costs. Several data indicate that left ventricular ejection fraction alone is not a sufficient criterion for a proper identification of patients who could benefit most from ICD. Numerous findings show that genetic analysis and characterization of myocardial fibrosis with magnetic resonance imaging allow an important improvement of this process.
Competing Interests: Conflict of interest: None declared.
(© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.)